Brovana and Other Drugs for Patients with COPD

What you'll learn

Course overview

BROVANA is approved for the twice-daily, long-term maintenance treatment of bronchoconstriction in patients with COPD, which includes chronic bronchitis and emphysema. BROVANA represents an exciting treatment option for the millions of patients with COPD. Until BROVANA was approved, patients requiring nebulized bronchodilator treatment only had short-acting bronchodilators to choose from as a nebulized treatment option. BROVANA is an FDA-approved long-acting bronchodilator for use with a nebulizer.